Zobrazeno 1 - 10
of 471
pro vyhledávání: '"V, Cour"'
Autor:
Estelle, Faucher1,2 (AUTHOR), Alexandra, Demelos1,2 (AUTHOR), Emilie, Boissady1,2 (AUTHOR), Yara, Abi Zeid Daou1,2 (AUTHOR), Lidouren, Fanny1,2 (AUTHOR), Vigué, Bernard3 (AUTHOR), Aurore, Rodrigues3 (AUTHOR), Bijan, Ghaleh1,2 (AUTHOR), Renaud, Tissier1,2 (AUTHOR), Kohlhauer, Matthias1,2 (AUTHOR) matthias.kohlhauer@vet-alfort.fr
Publikováno v:
Scientific Reports. 10/19/2024, Vol. 14 Issue 1, p1-10. 10p.
Autor:
Roldan-Valadez, Ernesto1 (AUTHOR), Leslie-Marisol-Gonzalez-Hermosillo2 (AUTHOR), Mendoza-Lopez, Abril-Carolina3 (AUTHOR)
Publikováno v:
Neurology India. Jan/Feb2023, Vol. 71 Issue 1, p164-165. 2p.
Publikováno v:
Melanoma Research. 2:147-152
Fotemustine is a new chloronitrosourea which is active against disseminated malignant melanoma (DMM), and especially against cerebral metastases (CM). This efficacy has been widely demonstrated through many phase II studies. A multicentre trial of mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a8860525fedd4169621fbd1f7573edbd
https://doi.org/10.1097/00008390-199209000-00001
https://doi.org/10.1097/00008390-199209000-00001
Autor:
J. P. Bizzari, G. Cohen-Alloro, J. C. Bousquet, K. Aigner, B. Audhuy, Cecil O. Borel, D. Buthiau, David Khayat, Jacquillat C, M. Weil, Gérard Auclerc, V. Cour
Publikováno v:
American Journal of Clinical Oncology. 14:400-404
Fotemustine is a new nitrosourea which has shown some efficacy on disseminated malignant melanoma (DMM) (24.2% response rate (RR) among 153 patients in a Phase II trial) but little activity on hepatic metastasis (8.8% RR). In order to improve those p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a43627cd6daf5a406f8b264a338b5c1c
https://doi.org/10.1097/00000421-199110000-00008
https://doi.org/10.1097/00000421-199110000-00008
Autor:
H. Langenbahn, V. Cour
Publikováno v:
Oncology Research and Treatment. 13:7-11
Fotemustin ist ein von Servier, Frankreich, neu entwickeltes Derivat des Chloro-Nitroso-Harnstoffs, das chemisch durch Verknupfung mit einem Phosphonsaurerest und damit verbundener hoher Lipophilie ge
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e9cd14ab8340cc1cf3e9e3b5c9d0eb6
https://doi.org/10.1159/000216710
https://doi.org/10.1159/000216710
Autor:
H. Ludwig, K. Havemann, K. Pollow, B. Kornhuber, G. Maschmeyer, M.E. Heim, H. Deicher, W. Hiddemann, H. Wilke, L. Hoffmann, F. Overkamp, K. Lennert, R. Waldmann, M.v. Bülow, H. Gisslinger, H. Köppler, W. Bätz, H. Stein, A. Grothey, E. Fritz, U. Cammerer, M. Fritz, H. Flechtner, J. Stirbu, S. Kunz, D.K. Hossfeld, L. Edler, G.v. Ingersleben, D. Schmähl, C. Gropp, S. Verhees, W. Queißer, M.R. Berger, E. Busse, R. Herrmann, J. Selbach, P. Drings, S. Oehl, H. Konyar, U. Bruntsch, D. Hossfeld, I.-M. v. Broen, R. Holle, V. Cour, H. Link, D. Adam, F. Trux, A. Sinop, H. Kuhn, W. Zeller, E.U. Steinhauer, E. Neeser, B. Steinke, P. Unterburger, K. Schumacher, J.P. Obrecht, B. Mentges, P. Preusser, H. Langenbahn, R. Coldewey, M. Fink, A. Ganser, E. Lötzke, J. Hartlapp, R. Pfab, K. Höffken, M. Flasshove, M. Helmerking, H. J. Schmoll, D. Peest, W. Noder, H. Kotzmann, D. Hoelzer, H.O. Klein, E.D. Kreuser, H.H. Goßmann, H.J. Weh, H.-J. Grill, H. Ehrhart, R. Hein, K.H. Pflüger, C.N. Gutt, E. Heidemann, I. Eschenbach, K. Possinger, P. Meyer
Publikováno v:
Oncology Research and Treatment. 13:57-60
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a3331db1962955371764c52860abd3c
https://doi.org/10.1159/000216722
https://doi.org/10.1159/000216722
Publikováno v:
PharmacoEconomics. 6
Lenograstim is a recombinant colony-stimulating factor that has been shown to be a useful adjunctive agent in cancer chemotherapy. Clinical trials have demonstrated the efficacy of lenograstim in correcting chemotherapy-induced neutropenia and associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd11f9f871cce4c0a09835cb6c5d32d3
https://pubmed.ncbi.nlm.nih.gov/10155596
https://pubmed.ncbi.nlm.nih.gov/10155596
Publikováno v:
European journal of cancer (Oxford, England : 1990). (2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3af7cf5eb20f1997ecd08c37b020cd0
https://pubmed.ncbi.nlm.nih.gov/8422299
https://pubmed.ncbi.nlm.nih.gov/8422299
Publikováno v:
Melanoma research. 2(3)
Fotemustine is a new chloronitrosourea which is active against disseminated malignant melanoma (DMM), and especially against cerebral metastases (CM). This efficacy has been widely demonstrated through many phase II studies. A multicentre trial of mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::14acbb494e7365f79c1da3ab85ece98a
https://pubmed.ncbi.nlm.nih.gov/1450667
https://pubmed.ncbi.nlm.nih.gov/1450667
Publikováno v:
Cancer chemotherapy and pharmacology. 31(2)
Fotemustine is a new nitrosourea derivative that contains an alpha-aminophosphonic acid and has a short half-life and a high plasma clearance. As myelosuppression occurs as the dose-limiting toxicity, local drug delivery has been investigated in the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2b4abcd148e507c8533c7b1f7f1f4f2
https://pubmed.ncbi.nlm.nih.gov/1451232
https://pubmed.ncbi.nlm.nih.gov/1451232